Investigating how a diabetes medication affects heart health
PPARgamma Coregulators in Rosiglitazone-Induced Cardiovascular Disease
['FUNDING_FELLOWSHIP'] · UNIVERSITY OF KENTUCKY · NIH-11069759
This study is looking at how the diabetes medication Rosiglitazone affects heart health and could lead to heart failure, especially by exploring how different diets might change the way a specific protein works in the body, which could help find ways to reduce any heart problems caused by the medication.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF KENTUCKY (nih funded) |
| Locations | 1 site (LEXINGTON, UNITED STATES) |
| Trial ID | NIH-11069759 on ClinicalTrials.gov |
What this research studies
This research explores the effects of the diabetes medication Rosiglitazone on heart health, particularly how it may lead to heart failure in some patients. The study focuses on a protein called PPARγ, which plays a crucial role in regulating fat and heart tissue functions. Researchers will examine how different diets influence the interactions of PPARγ with other proteins and how these interactions may contribute to heart problems. By understanding these mechanisms, the research aims to identify potential ways to mitigate the adverse effects of Rosiglitazone.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with type 2 diabetes who are currently using or have used Rosiglitazone.
Not a fit: Patients who do not have type 2 diabetes or those who have never used Rosiglitazone may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer diabetes treatments that do not compromise heart health.
How similar studies have performed: Previous research has shown that understanding the molecular mechanisms of diabetes medications can lead to significant improvements in patient safety and treatment efficacy.
Where this research is happening
LEXINGTON, UNITED STATES
- UNIVERSITY OF KENTUCKY — LEXINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BATES, EVELYN A — UNIVERSITY OF KENTUCKY
- Study coordinator: BATES, EVELYN A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: adult onset diabetes, Adult-Onset Diabetes Mellitus